Peloton Therapeutics
2011
FOUNDED
PRIVATE
STATUS
41-50
EMPLOYEES
Series E
LATEST DEAL TYPE
$150M
LATEST DEAL AMOUNT
17
INVESTORS
Description
Developer of early-stage cancer drugs intended to target unexploited molecular vulnerabilities. The company's drugs drive disease which have eluded conventional small molecule approaches, enabling patients with cancer and other serious or life-threatening conditions to avail oral drugs without any side effects.
Website
Formerly Known As
Damascus Pharmaceuticals
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 2330 Inwood Road
- Suite 226
- Dallas, TX 75235
- United States
+1 (972) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Peloton Therapeutics’s full profile, request a free trial.
Peloton Therapeutics Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC (Series E) | 20-Feb-2019 | $150M | 00000 | 00000 | Completed | Generating Revenue |
| 6. Later Stage VC (Series D) | 14-Mar-2017 | 000.00 | 00000 | 00000 | Completed | Clinical Trials - Phase 2 |
| 5. Grant | 05-Aug-2016 | 0000 | 000.00 | Completed | Clinical Trials - Phase 2 | |
| 4. Later Stage VC (Series C) | 05-Nov-2014 | 000.00 | 000.00 | 000.00 | Completed | Clinical Trials - Phase 1 |
| 3. Early Stage VC (Series B) | 18-Dec-2013 | 000.00 | 000.00 | 000.00 | Completed | Startup |
| 2. Grant | $11M | $18M | Completed | Startup | ||
| 1. Early Stage VC (Series A) | 27-Jul-2011 | $18M | $18M | 0000 | Completed | Startup |
Peloton Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series E | 00,000,000 | 00.000000 | 00.0 | 00.00 | 00.00 | 00 | 00.00 | 000 |
| Series D | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series C | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series B | 10,080,000 | $0.000100 | $0.1 | $1.25 | $1.25 | 1x | $1.25 | 7.68% |
| Series A | 17,100,000 | $0.000100 | $0.08 | $1 | $1 | 1x | $1 | 13.03% |
Peloton Therapeutics Investors (17)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| BVF Partners | Hedge Fund | Minority | 000 0000 | 000000 0 | ||
| Curative Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Driehaus Capital Management | Corporation | Minority | 000 0000 | 000000 0 | ||
| EcoR1 Capital | Hedge Fund | Minority | 000 0000 | 000000 0 | ||
| Eventide Asset Management | Asset Manager | Minority | 000 0000 | 000000 0 |
Peloton Therapeutics Executive Team (15)
1 Former Executive
You’re viewing 5 of 15 executives. Get the full list »Peloton Therapeutics Board Members (13)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Brett Ringle JD | Remeditex Ventures | Board Member | 000 0000 | |
| David Chang Ph.D | Self | Board Member | 000 0000 | |
| David Goeddel Ph.D | The Column Group | Chairman | 000 0000 | |
| Helen Kim | The Column Group | Board Member | 000 0000 | |
| James Tananbaum MD | Foresite Capital Management | Board Member & Advisor | 000 0000 |
1 Former Board Member
You’re viewing 5 of 13 board members. Get the full list »